Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

AbbVie’s deal flop and NFL high-profile draft busts have a lot in common.

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

Report on how AI is redefining market landscape - The global gastroparesis drugs market  size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated ...

The continent is being drenched in an avalanche of medical disinformation with the aim of undermining western influence ...

GlaxoSmithKline Pharmaceuticals and Sasken Technologies have released their financial results for the quarter that ended on ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.